In the G361 human melanoma model, only 95EtOH significantly reduced tyrosinase activity (relative fold change of 2.14 ± 0.19), reaching levels comparable to arbutin and kojic acid treatment (relative fold changes of 2.15 ± 0.40 and 2.27 ± 0.22, respectively), as illustrated in the 96-well plate assay results shown in Figure 4e. The gene discussed is TYR; the disease is melanoma.